NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
An orally bioavailable pentafluoroethyl derivative of a mifepristone-related steroid with antiprogestagenic activity. Lonaprisan is a pure, highly receptor-selective progesterone receptor (PR) antagonist; binding of this agent to PRs inhibits PR activation and the associated proliferative effects. Unlike many other antiprogestins such as mifepristone, this agent does not appear to convert to an agonist in the presence of protein kinase A (PKA) activators and shows high antiprogestagenic activity on both progesterone receptor (PR) isoforms PR-A and PR-B.
Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonym: progesterone receptor antagonist ZK 230211 Code name: ZK 230211 Chemical structures: 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluro-17-hydroxy-19-nor-17α-pregna-4,9- dien-3-one
19-norpregna-4,9-dien-3-one, 11-(4-acetylphenyl)-20,20,21,21,21-pentafluro-17- hydroxy-, (11β,17α)-